Reviva Pharmaceuticals Holdings Inc
11:30 AM - 11:45 AM (EST), Monday, February 6, 2023 ・ Music Box
We are a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases.
Our pipeline currently has two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house using our chemical genomics driven technology platform. We have been granted composition of matter patents for both RP5063 and R1208 in the United States (U.S.), Europe, and several other countries.
Our pipeline currently has two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house using our chemical genomics driven technology platform. We have been granted composition of matter patents for both RP5063 and R1208 in the United States (U.S.), Europe, and several other countries.
Ticker:
RVPH
Exchange:
NASDAQ
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2006
Main Therapeutic Focus:
CNS/Neurological
Lead Product in Development:
Brilaroxazine
Development Phase of Primary Product:
Phase III
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Speaker
